Jump to content

Genoveffa Franchini

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 19:10, 23 February 2022 (Add: newspaper. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | Suggested by Whoop whoop pull up | Category:HIV/AIDS researchers | #UCB_Category 168/224). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Genoveffa Franchini
Alma materUniversity of Modena and Reggio Emilia (MD)
Scientific career
FieldsHematology, retrovirology
InstitutionsNational Cancer Institute

Genoveffa Franchini is an Italian-American hematologist and retrovirologist. She is a senior investigator in the vaccine branch and head of the animal models and retroviral vaccines section at the National Cancer Institute. Franchini has pioneered research on oncogenes and human retroviruses. She researches HIV vaccine development and translational methods of disease prevention.

Early life and education

As a teenager in Italy, Franchini intended to conduct service work as a missionary nun. Her focus later shifted to biology and medicine as a means to help patients.[1] She completed a doctor of medicine at University of Modena and Reggio Emilia in 1977.[2] She was a postdoctoral fellow at her alma mater in the hematology institute from 1977 to 1979.[2]

Career

Franchini is a hematologist and retrovirologist.[3] She began working at the National Cancer Institute (NC) in 1979 as a research fellow.[1] Franchini is a senior investigator in the vaccine branch at NCI's Center for Cancer Research. Since 1997, Franchini is head of the animal models and retroviral vaccines section.[3][2]

Research

Franchini has pioneered research on oncogenes and human retroviruses (HTLVs and HIVs). She has made numerous achievements in virology and translational approaches to prevent human diseases caused by retroviruses. Her work has furthered the understanding of HIV and HTLV-1 pathogenesis, leading to the identification and characterization of new viral genes for HIV and HTLV-1 and their functions. Franchini's accomplishments in HIV vaccine development include the pre-clinical that led to the first vaccine trial in 16,000 volunteers in Thailand, that has demonstrated significant, though limited, protection against HIV acquisition. Her basic work in immunological mechanisms of protection furthered the understanding of the efficacy of the currently available smallpox vaccine in primates. She also has pioneered strategies to down-modulate regulators of immune response in HIV-1-infected individuals, using the macaque model of SIV infection.[3]

Awards and honors

Franchini was elected to the American Society for Clinical Investigation in 1990. In 2007, she was elected to the Association of American Physicians.[2]

References

  1. ^ a b "Federal Faces: Genoveffa Franchini". Washington Post. 2012-06-18. Retrieved 2020-04-02.
  2. ^ a b c d "CV" (PDF). Osservatorio Nazionale sulla Salute della Donna. 2017.
  3. ^ a b c "Genoveffa Franchini, M.D." Center for Cancer Research. 2014-08-12. Retrieved 2020-04-02.
Public Domain This article incorporates public domain material from websites or documents of the National Institutes of Health.